MITOMYCIN C
 |
|
|
Package(a):
VIALS: 10 x 2 mg.
Dosage(a):
Content of 1 vial to be dissolved before use.
Intermittent administration: For adults, administer I.V. 4 to 6 mg (potency) once or twice weekly.
Consecutive administration: For adults, administer I.V. 2 mg (potency) once daily.
Large dose intermittent administration: 10 to 30 mg at one to three (or more) week intervals.
Combined use: For adults, 2 to 4 mg once or twice weekly in combination with other anticancer agents.
Bladder cancer: Administer intravesically 4 to 10 mg (potency) once daily or every two days.
The dose may be adjusted according to the age of patients and severity of symptoms. See prescribing information for full details.
Prescribing Restrictions:
Package(b):
VIALS: 5 x 10 mg.
Dosage(b):
Content of 1 vial to be dissolved before use.
Intermittent administration: For adults, administer I.V. 4 to 6 mg (potency) once or twice weekly.
Consecutive administration: For adults, administer I.V. 2 mg (potency) once daily.
Large dose intermittent administration: 10 to 30 mg at one to three (or more) week intervals.
Combined use: For adults, 2 to 4 mg once or twice weekly in combination with other anticancer agents.
Bladder cancer: Administer intravesically 4 to 10 mg (potency) once daily or every two days.
The dose may be adjusted according to the age of patients and severity of symptoms. See prescribing information for full details.
Prescribing Restrictions: None
Indications:
Remission of subjective and objective symptoms associated with the following diseases: Chronic lymphocytic leukemia, chronic myelocytic leukemia, gastric, colorectal cancer, lung cancer, pancreatic cancer, liver cancer, cervical cancer, cancer of the endometrium, breast cancer, head and neck tumor and bladder tumor.
Contra-Indications:
History of serious hypersensitivity to any of the components of the product. Thrombocytopenia, coagulation disorders and increased bleeding tendency.
Special Precautions:
May produce serious adverse reactions, therefore patients should be closely monitored. Particular attention should be paid to the manifestation or aggravation of both infection and bleeding tendency. Administration to children. Patients with one or several of the following: hepatic disorder, renal disorder, bone marrow suppression, infectious disease, varicella (fatal systemic disorders may occur). Pregnancy and lactation: Not recommended to pregnant women. Breast-feeding should be discontinued. Intravenous administration should be carried out as slowly as possible. Not compatible with low pH injectable preparations. See prescribing information for full details.
Side Effects:
Leukocytopenia, thrombocytopenia, hemorrhage, microangiopathic hemolytic anemia. Hepatic disorders. Hemalytic uremic syndrome or proteinuria, hematuria, edema, hypertension. Anorexia, nausea and vomiting, stomatitis. Cystitis, hematuria or atrophy of bladder caused by bladder instillation therapy. See prescribing information for full details.
Drug Interactions:
None listed.
